NewEdge Advisors
FLNA icon

NewEdge Advisors’s Filana Therapeutics FLNA Stock Holding History

NewEdge Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.37K Sell
1,550
-26,750
-95% -$25.2K ﹤0.01% 4060
2026
Q2 		$33.7K Buy
28,300
+25,000
+758% +$35.6K ﹤0.01% 3217
2026
Q1 		$5.58K Sell
3,300
-725
-18% -$1.49K ﹤0.01% 3561
2025
Q4 		$7.97K Sell
4,025
-300
-7% -$960 ﹤0.01% 3533
2025
Q3 		$12.6K Hold
4,325
– – ﹤0.01% 3262
2025
Q2 		$7.83K Hold
4,325
– – ﹤0.01% 3277
2025
Q1 		$6.49K Buy
4,325
+1,750
+68% +$4.42K ﹤0.01% 3226
2024
Q4 		$6.08K Buy
2,575
+2,075
+415% +$36.4K ﹤0.01% 3177
2024
Q3 		$14.7K Hold
500
– – ﹤0.01% 2822
2024
Q2 		$6.18K Buy
500
+300
+150% +$6.32K ﹤0.01% 3021
2024
Q1 		$4.06K Buy
200
+150
+300% +$3.46K ﹤0.01% 3206
2023
Q4 		$1.13K Hold
50
– – ﹤0.01% 3446
2023
Q3 		$832 Hold
50
– – ﹤0.01% 3195
2023
Q2 		$1.23K Sell
50
-400
-89% -$9.6K ﹤0.01% 3209
2023
Q1 		$10.9K Hold
450
– – ﹤0.01% 2540
2022
Q4 		$13 Buy
+450
New +$16.2K ﹤0.01% 3671

Other funds holding FLNA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $121B AUM 21.47% 1-Year Est. Return

NewEdge Advisors's FLNA Position: Q3 2026 in Review

NewEdge Advisors reduced its Filana Therapeutics (FLNA) stake by 95% in Q3 2026, selling an estimated $25.2K and leaving 1,550 shares worth $1.37K. The position accounts for ﹤0.01% of the portfolio, ranked #4060.

NewEdge Advisors first reported a position in FLNA in Q4 2022 and has held it in 16 quarters since. The position peaked at $33.7K in Q2 2026. 60 funds tracked by Wall St. Rank hold FLNA as of Q3 2026.

  • NewEdge Advisors held 1,550 shares of Filana Therapeutics worth $1.37K as of Q3 2026.
  • NewEdge Advisors sold 26,750 Filana Therapeutics shares in Q3 2026, an estimated $25.2K.
  • Filana Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q3 2026, its #4060 holding.
  • NewEdge Advisors first reported a position in Filana Therapeutics in Q4 2022 and has held it in 16 quarters since.
  • NewEdge Advisors's Filana Therapeutics position peaked at $33.7K in Q2 2026.
  • 60 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2026.

Based on NewEdge Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.